A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)



Status:Recruiting
Healthy:No
Age Range:18 - Any
Updated:2/24/2019
Start Date:May 25, 2018
End Date:May 2021
Contact:Medical Affairs
Email:medinfo@agios.com
Phone:833-228-8474

Use our guide to learn which trials are right for you!

An Open-Label Study To Evaluate the Efficacy and Safety of AG-348 in Regularly Transfused Adult Subjects With Pyruvate Kinase (PK) Deficiency

Study AG348-C-007 is a multicenter study designed to evaluate the efficacy and safety of
treatment with AG-348 in approximately 15-20 adult participants with pyruvate kinase
deficiency (PKD), who are regularly receiving blood transfusions. The study is comprised of
two parts. During the Part 1 Dose Optimization Period of the study, all participants will
start on a dose of 5 mg AG-348 administered twice daily. Over the course of Part 1 each
participant's dose will be optimized individually, up to a maximum dose of 50 milligrams
(mg), twice daily. During the Part 2 Fixed-Dose Period, participants will receive AG-348 at
their optimized dose from Part 1.


Inclusion Criteria:

- Informed consent;

- Male or female, aged 18 or older;

- Presence of at least 2 mutant alleles in the Pyruvate Kinase Liver and RBC (PKLR)
gene, of which at least 1 is a missense mutation;

- History of a minimum of 6 transfusion episodes in the 52-week period prior to date of
informed consent;

- Complete records of transfusion history for the 52 weeks prior to the date of informed
consent, including all transfusion dates, number of blood units transfused for all the
transfusions, and Hb concentrations within 1 week prior to transfusion for at least
80% of the transfusions;

- Have received at least 0.8 mg of oral folic acid daily for at least 21 days prior to
the first dose of study drug, to be continued daily during study participation;

- Have adequate organ function;

- Negative serum pregnancy test for women of reproductive potential;

- For women of reproductive potential as well as fertile men and their partners who are
women of reproductive potential: be abstinent or agree to use 2 forms of
contraception, 1 of which must be considered highly effective, from the time of giving
informed consent, during the study, and for 28 days following the last dose of AG-348;

- Willing to comply with all study procedures, in particular the individual transfusion
trigger (TT) calculated based on 52 weeks of transfusion history, for the duration of
the study.

Exclusion Criteria:

- Homozygous for the R479H mutation or have 2 non-missense mutations, without the
presence of another missense mutation, in the PKLR gene;

- Significant medical condition that confers an unacceptable risk to participate in the
study, and/or that could confound the interpretation of the study data;

- History of transfusions occurring on average more frequently than once every 3 weeks
during the 52 weeks prior to date of informed consent;

- Splenectomy scheduled during the study treatment period or have undergone splenectomy
within 12 months prior to signing informed consent;

- Currently enrolled in another therapeutic clinical trial. Prior participation in the
PK Deficiency Natural History Study (NHS) (NCT02053480) or PK Deficiency Registry is
permitted;

- Exposure to any investigational drug, device, or procedure within 3 months prior to
the first dose of study drug;

- Prior bone marrow or stem cell transplant;

- Currently pregnant or breastfeeding;

- History of major surgery within 6 months of signing informed consent;

- Currently receiving medications that are strong inhibitors of CYP3A4, strong inducers
of CYP3A4, strong inhibitors of P-glycoprotein (P-gp), or digoxin (a P-gp sensitive
substrate medication) that have not been stopped for a duration of at least 5 days or
5 times their half-lives (whichever is longer) prior to start of study drug;

- Currently receiving hematopoietic stimulating agents (eg, erythropoietins [EPOs],
granulocyte colony stimulating factors, thrombopoietins) that have not been stopped
for a duration of at least 28 days prior to the first dose of study drug;

- History of allergy to sulfonamides if characterized by acute hemolytic anemia, drug
induced liver injury, anaphylaxis, rash of erythema multiforme type or Stevens-Johnson
syndrome, cholestatic hepatitis or other serious clinical manifestations;

- Allergy to AG-348 or its excipients;

- Currently receiving anabolic steroids, including testosterone preparations, within 28
days prior to the first dose of study drug.
We found this trial at
6
sites
201 Dowman Dr
Atlanta, Georgia 30303
(404) 727-6123
Emory University Emory University, recognized internationally for its outstanding liberal artscolleges, graduate and professional schools,...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
?
mi
from
Boston, MA
Click here to add this to my saved trials
825 Eastlake Ave E
Seattle, Washington 98109
(206) 288-7222
Seattle Cancer Care Alliance Seattle Cancer Care Alliance (SCCA) is a cancer treatment center that...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Oakland, California 94609
?
mi
from
Oakland, CA
Click here to add this to my saved trials
Palo Alto, California 94304
?
mi
from
Palo Alto, CA
Click here to add this to my saved trials
200 Elizabeth Street
Toronto, M5G 1J6
?
mi
from
Toronto,
Click here to add this to my saved trials